Refractory Precursor T Lymphoblastic Lymphoma Leukemia C0854859
An aggressive blood cancer of immature T-cells that has become resistant to standard chemotherapy. It mainly affects adolescents and young adults. Treatment is difficult and often relies on clinical trials.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- critical
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Dyspnea
Fatigue
(hematologic)Pallor
(hematologic)Bone pain
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Salvage chemotherapy regimen
Intensive multi-agent chemotherapy protocols designed to induce remission in refractory disease. Examples include FLAG-ida, nelarabine-based combinations, or other novel regimens.
Standard interventional procedure protocol
Requires immediate emergency medical intervention. Do not delay treatment.
Allogeneic stem cell transplantation
Potentially curative approach for eligible patients achieving remission. Involves high-dose chemotherapy followed by infusion of donor stem cells. Graft-versus-leukemia effect provides additional anti-tumor activity.
Additional treatment options
CAR-T cell therapy
Chimeric antigen receptor T-cell therapy targeting CD7 or other surface antigens. Involves leukapheresis, conditioning chemotherapy, and infusion of engineered autologous T-cells.
medicationTargeted therapy for actionable mutations
If molecular profiling reveals targetable mutations, agents such as tyrosine kinase inhibitors may be employed. Requires comprehensive genomic testing prior to selection.
medicationPalliative and supportive care integration
Early integration of palliative care services to manage symptom burden, provide psychosocial support, and assist with treatment decision-making throughout the disease course.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is Refractory Precursor T Lymphoblastic Lymphoma Leukemia C0854859?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
NCCN Clinical Practice Guidelines in Oncology. Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. NCCN Guidelines Version 3.2023.
Mauguen A, et al. Chemotherapy with or without nelarabine in treating adults with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. J Clin Oncol. 2022.
Marks DI, et al. Relapsed and refractory acute lymphoblastic leukemia in adults: a review of current therapies and future directions. Blood. 2021.
Chiaretti S, et al. Meta-analysis of salvage therapies in relapsed/refractory adult T-cell acute lymphoblastic leukemia. Leukemia. 2020.
Medication Comparisons
Compare medications used to treat Refractory Precursor T Lymphoblastic Lymphoma Leukemia C0854859. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy